Condition: Schizophrenia · Sponsor: Central South University
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.
This description comes directly from the study's public registry record.
Renrong Wu, M.D. Ph.D · +8615874179855 · wurenrong@csu.edu.cn
Jing Huang, M.D. Ph.D · 15874290980 · jinghuangserena@csu.edu.cn
Always discuss trial participation with your own doctor first.
| Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| The Second People's Hospital of Dali Bai Autonomous Prefecture | Dali, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05783063